About Us

MABT was founded in 2011 with the simple goal of making a meaningful difference on the lives of patients, families and communities worldwide. We are especially excited about our work on neurodegenerative conditions such as Alzheimer’s, Parkinson’s and ALS.

Mid-Atlantic BioTherapeutics is committed to pushing the boundaries of scientific understanding and therapeutic efficacy to address an unmet need for diseases that are hard to treat. By leveraging the power of biotechnology and artificial intelligence, we believe that we may be able to treat currently incurable diseases.

MABT has multiple novel proprietary technologies that we test for the goal of having a profound impact on hard to treat diseases. We were even the first company ever to qualify for Orphan Drug Designation for Rabies, the world’s most deadly disease with our proprietary technology platform Immunotherapy, IMT504.

Everyday, MABT works towards a brighter future. We are concentrating on the clinical development and commercialization of treatments for hard to treat disorders, especially neurological diseases.

Press Play

OUR CEO

Welcome to Mid-Atlantic BioTherapeutics (MABT), where innovation meets compassion in the pursuit of transforming healthcare. At MABT, we are dedicated to advancing cutting-edge therapies for some of the most challenging neurological and infectious diseases facing society today.

At the heart of our innovation lies our advanced scientific approach. MABT combines deep expertise in biotechnology with state-of-the-art AI-driven computational methods to accelerate drug discovery and development. This interdisciplinary approach allows us to identify promising therapeutic targets more efficiently and design optimized therapies with enhanced precision.

This is not just science; it’s a journey of hope, compassion, and relentless dedication. I invite you to join us on this incredible journey.

-Dr. David Horn

Targets

Alzheimer’s

Alzheimer’s disease is a chronic neurodegenerative disorder that primarily affects the brain, leading to a progressive decline in memory, thinking skills, and cognitive abilities.

Parkinson's

Parkinson’s disease is a neurodegenerative disorder that primarily affects the central nervous system. It is named after James Parkinson, the British physician who first described its symptoms in 1817.

ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects the nerve cells responsible for controlling voluntary muscle movement.

Infectious Disease

New treatments and vaccines are needed to solve very hard to treat diseases, such as rabies, COVID and influenza.  These diseases are often fatal and current therapies and vaccines need to be greatly improved. 

Leadership

David Horn, M.D., F.A.C.P., F.I.D.S.A. (CEO & Founder):

Dr. Horn brings over 30 years of research & clinical expertise in infectious diseases. He has held senior positions at Bristol-Myers Squibb, Merck, Thomas Jefferson University, and continues to serve as an Industry Consultant. David is a board-certified physician in internal medicine and infectious diseases, and he is an expert in clinical development and medical affairs. Dr. Horn completed his fellowship training in infectious diseases at Brown University, Providence, RI. He is also a fellow of the American College of Physicians and a fellow of the Infectious Diseases Society of America. Dr. Horn has authored or co-authored numerous publications concerning fungal diseases, bacterial infections, HIV infection and AIDS, tuberculosis, medical informatics and sepsis.

Dave Jobes, Ph.D. (President & Co-Founder):

Dr. Jobes brings over 25 years of research and business development expertise in the healthcare and pharmaceutical industry. Dr. Jobes received his Ph.D. in cell and molecular biology from Tulane University and completed a postdoctoral and research fellowship at the National Institutes of Health (NIH). Dr. Jobes has held numerous senior-level research and/or business development positions at a range of biotech companies and is co-founder of three of them. Dr. Jobes is a well-published scientist and successful business development executive, having completed >$500M in transactions (buy and sell side).

Jean-Pierre Gagnon, Ed.D. (Senior VP of Operations and Co-Founder):

Dr. Gagnon has over 35 years of executive experience in U.S. and International Sales & Marketing, Commercial (P&L) Operations (including President – Merck Mexico). During his career at Merck, Dr. Gagnon was the architect for the launches of several multi-billion dollar brands in the US and led large commercial organizations in Canada, US and Latin America. Dr. Gagnon led the launches and the commercialization of the most successful vaccines and anti-infective brands created by Merck over the last 25 years. In 2013, he graduated with a doctoral degree in Global Business Leadership from the University of Pennsylvania (in collaboration with the Wharton Business School and Thunderbird University). Over the years, Dr. Gagnon has developed an extensive global network of thought leaders, business leaders, human and animal health experts, practitioners, and academicians.


News

Mid-Atlantic BioTherapeutics, Inc. Launches $5 Million Regulation D 506(c) Funding Round to Support Clinical Program Acceleration and Expand the Company’s Global Reach and Market Presence

DOYLESTOWN, Pa., Oct. 15, 2024 /PRNewswire/ — Mid-Atlantic BioTherapeutics, Inc. (the “Company“), a clinical-stage biotechnology company specializing in cutting-edge immunotherapies and central nervous system (“CNS“) disorder treatments, today announced the commencement of a fundraising round …

CONTACT

Please enable JavaScript in your browser to complete this form.
Name

Mid-Atlantic BioTherapeutics
3805 Old Easton Road
Doylestown, PA 18902
USA